Related Experiment Video
Updated: Dec 9, 2025
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
Design of a multi-epitope peptide vaccine candidate against chandipura virus: an immuno-informatics study
Daya V Pavitrakar1, Nitin M Atre1, Anuradha S Tripathy1
1ICMR - National Institute of Virology, Pune, India.
Insights
This study designed a multi-epitope peptide construct (MEC-CHPV) against Chandipura virus (CHPV) using immunoinformatics. In silico analysis confirmed its potential as a safe and immunogenic vaccine candidate against CHPV infection.
Area of Science:
- Virology
- Immunology
- Computational Biology
Background:
- Chandipura virus (CHPV) causes acute encephalitic syndrome (AES) in Indian children, with no current vaccines or therapies.
- CHPV outbreaks have been reported in India since 2003, highlighting the need for effective interventions.
Purpose of the Study:
- To design a multi-epitope peptide construct (MEC-CHPV) targeting key Chandipura virus proteins.
- To evaluate the immunogenicity, safety, and stability of the designed construct using in silico methods.
Main Methods:
- Identification and characterization of T-cell and B-cell epitopes from CHPV Nucleoprotein (N), Phosphoprotein (P), Matrix protein (M), and Glycoprotein (G).
- Design of a multi-epitope construct (MEC-CHPV) incorporating identified epitopes, a beta-defensin adjuvant, and in silico validation of physicochemical properties, antigenicity, and allergenicity.
- 3D structure prediction, molecular docking with TLR-3 and TLR-8, molecular dynamics simulations, in silico cloning, and immune simulation.
Main Results:
- A non-toxic, non-allergenic, and highly immunogenic multi-epitope construct (MEC-CHPV) was designed.
- Stable interactions were observed between MEC-CHPV and Toll-like receptors (TLR-3 and TLR-8).
- In silico immune simulation predicted a robust immune response, supporting MEC-CHPV as a potential vaccine candidate.
Conclusions:
- The immunoinformatics approach provides a cost-effective and time-efficient method for designing peptide vaccine candidates.
- The developed MEC-CHPV construct shows promise for future laboratory validation and potential development as a Chandipura virus vaccine.
Abstract:
Chandipura virus (CHPV) is an emerging pathogen responsible for acute encephalitic syndrome (AES) in pediatric population in India. Several outbreaks of CHPV have been reported from different states of India since the year 2003. At present there is no vaccine or therapeutic measures available to curtail the disease. In this study, we have identified both T-cell and B-cell epitopes of different antigenic proteins of CHPV like Nucleoprotein (N), Phosphoprotein (P) and Matrix protein (M) along with the immuno-dominant glycoprotein (G) and conducted in silico characterization for the same. The idea is to design a multi-epitope peptide construct using the epitopes, which were found to be non-toxic, non-allergenic and possessing high immunogenicity. The final multi-epitope construct named as: MEC-CHPV, comprised of β-defensin adjuvant at N-terminal for enhancement of immunogenicity followed by fourteen B-cell epitopes, four Helper T-cell epitopes and six Cytotoxic T-cell epitopes. The characterization of designed construct was carried out in terms of physicochemical parameters, antigenicity and allergenicity. The 3D structure prediction was performed. Molecular docking and molecular-dynamics simulation of MEC-CHPV with Toll like receptors (TLR-3 and TLR-8) showed stable interactions. In silico cloning of MEC-CHPV in pET30a(+) expression vector was also conducted using codon optimization. The in silico immune-simulation indicated a typical immune response against MEC-CHPV when used as a potential vaccine. This study provides a cost-effective and time-saving way to design a peptide vaccine candidate against CHPV using immuno-informatics approach. Development of the MEC-CHPV construct may pave the way for future laboratory experiments.Communicated by Ramaswamy H. Sarma.
